GSK's malaria vaccine to go to regulators in 2014
This article was originally published in Scrip
GlaxoSmithKline's pioneering malaria vaccine looks like it could arrive within two years. The company says it will file for approval of the RTS,S vaccine with the European Medicines Agency next year, based on the latest data from its large-scale Phase III trial. It added that the World Health Organization has indicated that a policy recommendation for the RTS,S malaria vaccine candidate is possible as early as 2015 if it is granted a positive scientific opinion by EMA, paving the way for decisions by African nations regarding large-scale implementation of the vaccine through their national immunization programs.
You may also be interested in...
A Phase III rare-disease hit for Sanofi marks the first of a number of orphan drug read-outs expected in the coming year.
Philadelphia is due to host the American Heart Association (AHA) meeting for the first time from 16-18 November, with the conference taking place in its condensed three-day format for just the second time. Scrip takes a look at the expected highlights.
Shares plummet as ObsEva announces it is discontinuing its IVF program for nolasiban after disappointing Phase III data from a European confirmatory study.